Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is a pioneer and leader in the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management (LAAM), and its innovative product line, experienced management team, and strong sales force position the company for durable revenue growth and profitability in the years ahead. The recent launch of the CryoSPHERE MAX device and favorable clinical trial results for the BOxX-NoAF technology add to AtriCure's already strong product portfolio, and we believe the company's current valuation does not adequately reflect its potential for continued success and market share expansion.

Bears say

AtriCure is facing strong competition in the market and may struggle to gain widespread acceptance, impacting their operating results. Additionally, rising healthcare costs and potential changes in payors' policies towards coverage and reimbursement could harm the company's ability to sell their products. The company's success is also dependent on positive clinical data and meeting strict regulatory requirements, which may not always be achievable.

AtriCure (ATRC) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 7 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.